A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

Recruiting now · Phase 1/Phase 2

Conditions studied: Multiple Myeloma

In brief

The purpose of this study is to evaluate the preliminary safety and determine the RP2D of mezigdomide in combination with elranatamab in participants with relapsed and refractory multiple myeloma (RRMM).

Key facts

Study ID

NCT06988488

Run by

Celgene

People needed

62

Starts

2025-10-07

Expected to finish

2027-06-03

Last updated by the study team

2026-05-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥18 with history of relapsed and refractory multiple myeloma (RRMM) treated with 2 to 4 prior lines of anti-myeloma therapy (Phase 1) or 1 to 3 prior lines of anti-myeloma therapy (Phase 2).
• Measurable MM by local laboratory.
• Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1.
• Adherence to contraception requirements.

You may not qualify if…

• Prior treatment with mezigdomide.
• Prior treatment with T cell engaging or T cell engager (TCE).
• Prior treatment with B cell-maturation antigen (BCMA)-targeting therapy, with the exception of participants who have received autologous BCMA-targeted CART-cell therapy> 6 months from the start of study therapy
• Other protocol-defined Inclusion/Exclusion criteria apply.

Where it is running

• The Christie NHS Foundation Trust — Manchester, United Kingdom (enrolling)
• Yale New Haven Hospital-Smilow Cancer Center — New Haven, Connecticut, United States (enrolling)
• Hackensack University Medical Center — Hackensack, New Jersey, United States (enrolling)
• University of Texas MD Anderson Cancer Center — Houston, Texas, United States (enrolling)
• Arthur J E Child Comprehensive Cancer Centre — Calgary, Alberta, Canada (enrolling)
• University College London Hospital — London, England, United Kingdom (enrolling)
• Royal Marsden Hospital (Sutton) — London, Sutton, United Kingdom (enrolling)
• University of Alabama at Birmingham — Birmingham, Alabama, United States (enrolling)
• QEII Health Sciences Centre - Victoria General Site — Halifax, Nova Scotia, Canada (enrolling)
• Princess Margaret Cancer Centre — Toronto, Ontario, Canada (enrolling)
• Universitaetsklinikum Carl Gustav Carus Dresden — Dresden, Germany (enrolling)
• Universitaetsklinikum Hamburg-Eppendorf — Hamburg, Germany (enrolling)
• Universitaetsklinikum Heidelberg — Heidelberg, Germany (enrolling)
• Evangelismos General Hospital of Athens — Athens, Attikí, Greece (enrolling)
• Alexandra General Hospital of Athens — Athens, Attikí, Greece (enrolling)
• St. Olavs Hospital — Trondheim, Sør-Trøndelag, Norway (enrolling)
• Sykehusapoteket Ull — Oslo, Norway (enrolling)
• Hospital Universitario Marqués de Valdecilla — Santander, Cantabria, Spain (enrolling)
• Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca — Salamanca, Spain (enrolling)
• Local Institution - 0026 — Vancouver, British Columbia, Canada
• Local Institution - 0030 — Suzhou, Jiangsu, China
• Local Institution - 0031 — Shanghai, Shanghai Municipality, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.